Published in Physician Business Week, October 12th, 2004
The results showed secondary patency of 83% and freedom of infection of 94% at 1 year in patients undergoing dialysis. These results were presented at the Advances in Tissue Engineering and Biology of Heart Valves Conference in Florence, Italy. CryoLife's SynerGraft AV access device, made of a bovine ureter, is only approved in Europe for dialysis patients.
Darby implanted the SynerGraft AV access device in 17 high-risk patients who failed previous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.